Noveko Announces Firm Orders Worth $18 Million for its Antimicrobial Face Masks and AZURO(TM) Sanitizers

Noveko International Inc. ("the Company") is pleased to announce that the value of its firm orders for its Noveko(TM) antimicrobial face masks and respirators and AZURO(TM) hand sanitizers, for the period beginning July 1st, 2009, currently totals approximately $18 million, i.e. $12 million for face masks and respirators and $6 million for sanitizers. This significant number of orders reflects the sharp increase in demand for the Company's antimicrobial products. The orders come mainly from various distributors, notably Eval Consulting, BLD Distribution L.L.C., Aerosys Technologies and Medi-Select.

The Noveko(TM) antimicrobial face masks and respirators and AZURO(TM) hand sanitizers will be delivered over the coming months to different markets such as Canada, the United States, Mexico, South America, Europe, the Maghreb, the Middle East and Asia

The sales of Noveko products are targeted to a variety of customers, including government entities, healthcare and educational institutions, airlines, aircraft manufacturers, companies operating in the real estate industry and various other entities that have opted for Noveko antimicrobial products as part of their contingency plans.

"We are particularly proud to see that the different distribution agreements and partnership opportunities we have developed in recent months are yielding benefits. Furthermore, we are pursuing negotiations for major additional orders. We also remain on the lookout for new partnership opportunities to step up our product manufacturing and marketing in promising segments. In this regard, we are in talks with targeted companies that could become ideal partners for the further development and diversification of our markets and product offering," indicated Alain Bolduc, President and Chief Operating Officer of the Company.

Profile

Noveko International Inc. offers innovative solutions in the environmental and medical fields worldwide. Through its subsidiaries, the Company specializes primarily in the following business segments: the development, manufacturing and marketing of derivative products from its patented antimicrobial filtration technology, including air filters, surgical masks and respirators, along with other products with antimicrobial properties such as AZURO(TM) hand sanitizers - and the development, manufacturing and marketing of medical equipment, primarily portable real-time ultrasound scanners for use in human and veterinary medicine.

Certain statements set forth in this press release constitute forward-looking statements. In some cases, these statements are identified by the use of terms such as "may", "could", "might", "intend", "should", "expect", "project", "plan", "believe", "estimate" or other comparable variants. These statements are based on the information available at the time they are written, on assumptions made by management and on the expectations of management, acting in good faith, regarding future events, including those relating to economic conditions, fluctuations in exchange rates and operating expenses, and the absence of unusual events entailing supplementary expenditures. Although management considers these assumptions and expectations reasonable based on the information available at the time they are written, they could prove inaccurate. Forward-looking statements are also subject, by their very nature, to known and unknown risks and uncertainties such as those related to the industry, acquisitions, labor relations, credit, key officers, supply and product liability. The actual results of Noveko International Inc. could differ materially from those indicated or underlying these forward-looking statements. The reader is therefore recommended not to unduly rely on these forward-looking statements. Forward-looking statements do not reflect the potential impact of special items, any business combination or any other transaction that may be announced or occur subsequent to the date hereof. The Company undertakes no obligation to update or revise the forward-looking statements to account for new events or new circumstances, except where provided for by applicable legislation.

SOURCE: NOVEKO INTERNATIONAL INC.

Chantal Vennat, Director, Investor Relations and Corporate Communications, Noveko International Inc., (514) 875-0606; http://www.noveko.com